Valeant
Valeant announces strong Q3 results, will expand US contact lens plant
October 20, 2015Manufacturing and Production, Sales and Marketing Valeant, financial results, manufacturing, production
Valeant has announced plans to invest up to $150 million and add 200 jobs at its Bausch and Lomb plant …
Valeant receives court writ over US drug pricing
October 15, 2015Medical Communications, Sales and Marketing Drug pricing, Isuprel, Nitropress, US, Valeant, subpoena
Valeant Pharmaceuticals has disclosed that it has received two subpoenas in the US, demanding evidence concerning the pricing and distribution …
Valeant confirms $1bn deal for ‘female viagra’ creator Sprout
August 20, 2015Manufacturing and Production, Sales and Marketing Addyi, Sprout, Sprout Pharma, Sprout Pharmaceuticals, Valeant, flibanserin
Canada’s Valeant Pharmaceuticals has confirmed it will pay $1 billion to acquire Sprout Pharmaceuticals, the company behind the female libido …
Valeant in $800 million deal for Amoun Pharma
July 20, 2015Sales and Marketing Amoun, Egypt, MENA, Valeant, acquisitions
Valeant is striking out in the acquisitions market yet again, having agreed an $800 million deal to buy Egypt’s largest …
Valeant looking to buy Zoetis
June 26, 2015Sales and Marketing Actavis, Allergan, Valeant, Zoetis, brett wells
Canadian drugmaker Valeant Pharmaceuticals has made a move to acquire animal health company Zoetis. This is according to the Wall …
Actavis changes its name to Allergan
June 16, 2015Medical Communications, Sales and Marketing Actavis, Allergan, Botox, Valeant
Actavis has now officially changed its name to Allergan following the Ireland-based company’s recent acquisition of the botox maker. This …
Actavis and Valeant see FDA approval for IBS drugs
May 28, 2015Sales and Marketing Actavis, FDA, IBS, Valeant, brett wells
Both Actavis and Valeant have been shown the green light for their respective irritable bowel syndrome (IBS) treatments from the …
Endo lands a big fish with $8 billion Par Pharma deal
May 19, 2015Sales and Marketing Endo, Valeant, par pharma
Endo is switching strategies from attempting to buy specialist pharma firms, to generics, having announced a huge $8 billion deal …
Hundreds of jobs threatened after big pharma deals close
April 7, 2015Medical Communications, Research and Development, Sales and Marketing Deals, GSK, Jobs, Novartis, US, Valeant, job losses, redundancy, salix
Fresh from deals worth a combined $34 billion, GSK and Salix Pharmaceuticals have announced company restructures that have placed more …
Valeant sprints ahead of Endo to secure Salix
March 18, 2015Sales and Marketing Actavis, Canada, Endo, Valeant, Xifaxan, methylnaltrexone, rifaximin, salix
Salix Pharmaceuticals has accepted an improved $11.1 billion takeover swoop from Valeant Pharmaceuticals to beat rival bidder Endo International. The …
Endo attempts to outbid Valeant for Salix Pharma
March 12, 2015Sales and Marketing Endo, Valeant, merger, outbid, pharma, salix
Endo has joined the race for Salix, the firm that Valeant reached a $14.5 billion agreement to purchase last month. …
Valeant to buy Salix in $14.5 billion move
February 23, 2015Sales and Marketing Deals, Heptares, Valeant, mergers, salix, sosei
Valeant has agreed a deal to acquire US-based speciality manufacturer of gastrointestinal drugs Salix in a move worth around $14.5 …
Valeant recalls drug used on hospitalised infants
January 6, 2015Manufacturing and Production, Sales and Marketing Actavis, Allergan, FDA, Valeant, manufacturing, recall, ribavirin, virazole
North American drug firm Valeant Pharmaceuticals has issued a voluntary nationwide recall of Virazole due to microbial contamination. Virazole (ribavirin …
Actavis buys Allergan for $66 billion
November 18, 2014Medical Communications, Sales and Marketing Actavis, Allergan, Botox, Canada, Valeant, merger
The stately dance between Actavis and Allergan has culminated in the former buying the Botox manufacturer in a $66 billion …
Allergan eyeing Actavis buyout
November 13, 2014Medical Communications, Research and Development, Sales and Marketing Actavis, Allergan, Botox, Valeant, acquisition, buyout, merger
Allergan is attempting to block a recent Valeant hostile takeover bid by seeking the rumoured alternative merger deal with Actavis, …
Latest content
FibroFind appoints Lee Borthwick as CEO
